Home About Our Services Experience Publications News & Events Contact Us Downloads
OUR SERVICES

Health Economics

Patient-Reported Outcomes

Market Access and Outcomes Strategy

Health Preference Assessment

Pharmacoepidemiology and Risk Management
> Consulting
> Database Research
> Prospective Observational Research
> Literature Reviews
> Risk Management
> REMS
> EU-RMP

Drug Safety and Pharmacovigilance

Biometrics

Clinical and Medical Services

 

RTI-HS HomeOur ServicesPharmacoepidemiology and Risk Management › Risk Evaluation and Mitigation Strategies (REMS)

Risk Evaluation and Mitigation Strategies (REMS)

The Food and Drug Administration Amendments Act of 2007 (FDAAA) authorized the FDA to require sponsors to submit a risk evaluation and mitigation strategy (REMS) for drugs in cases in which the FDA determined that a REMS was necessary to ensure that the benefits of the drug would outweigh its risks.

We have applied our experience in developing and implementing risk management plans (RMPs) to helping our clients understand and meet requirements for REMS. Our REMS services include:

Consult on whether a REMS is required

Develop the REMS proposal

Implement the REMS

Assess and evaluate the REMS

Modify the REMS

 


 
CONTACT US

 
Elizabeth B Andrews, PhD
Vice President, Pharmacoepidemiology and Risk Management
Susana Perez-Gutthann, MD, PhD
Vice President, Global Head of Epidemiology
Kenneth J Rothman, DrPH
Distinguished Fellow, Vice President of Epidemiology Research
Pat Tennis, PhD
Senior Director, Epidemiology

US: +1.800.262.3011
Spain: +34.93.241.7766
UK: +44(0)161.232.3400
For a full list of scientific staff bios, click here.

 

Home | About | Our Services | Experience | Publications | News & Events | Contact Us | Downloads
©2008 RTI Health Solutions. All Rights Reserved.